TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET
One target, three approved-or-nearly-approved drugs, and a fourth wave. How TROP2 went from an obscure trophoblast antigen to the centre of breast and lung cancer treatment.
TROP2 is not a driver; it is an address. Its value comes entirely from what is delivered to it. The roadmap therefore tracks payload chemistry, the shift into first line, combination with immunotherapy, the unsolved selection problem, and bispecific successors.
- 1981-2015historic
Target discovery and antibody development
TROP2 identified on trophoblasts (1981); overexpression across epithelial cancers established in the 2000s. Immunomedics humanises the RS7 antibody and conjugates SN-38 (IMMU-132) with a moderately stable, hydrolysable linker designed to release payload in the tumour microenvironment.
- 2020-2021historic
Sacituzumab govitecan proves the target
ASCENT: OS 12.1 vs 6.7 months in pretreated metastatic TNBC; accelerated then full approval. Gilead acquires Immunomedics for $21B. Benefit irrespective of TROP2 IHC, so no companion diagnostic is required.
- 2023-2025current
Second entrant: datopotamab deruxtecan
Datopotamab deruxtecan carries the DXd payload at DAR 4 on a different anti-TROP2 antibody. TROPION-Breast01 (HR+, PFS only) and TROPION-Lung01 (mixed) produce narrow approvals (HR+ breast 2025; EGFR-mutant NSCLC 2025). Stomatitis and ocular toxicity define its profile versus sacituzumab's neutropenia and diarrhoea. Sacituzumab expands to HR+ (TROPiCS-02) but loses its urothelial indication.
- 2025-2026current
First line: three positive phase 3 trials
ASCENT-03 (sacituzumab, PD-1-ineligible), ASCENT-04 (sacituzumab + pembrolizumab, PD-L1+), and TROPION-Breast02 (Dato-DXd, PD-1-ineligible, first OS benefit) all read out positive, with FDA approvals in Q2 2026. TROP2 ADCs displace chemotherapy in first-line metastatic TNBC. TROPION-Breast05 (Dato-DXd + durvalumab) is pending.
- 2024-2027emerging
Third entrant: sacituzumab tirumotecan and the Merck programme
Kelun's sac-TMT, with a belotecan-derived payload and a more stable linker, is approved in China (2024) and licensed to Merck, which is running >10 phase 3 TroFuse trials across TNBC, HR+ breast, NSCLC, endometrial, and cervical cancer, often with pembrolizumab. FDA priority voucher July 2026; US approval expected to follow positive first-line TNBC data.
- 2026-2029emerging
Unsolved: selection, sequencing, resistance
IHC does not predict benefit. Cross-resistance among TOP1 payloads limits sequencing (T-DXd → sacituzumab or vice versa). TROP2 PET tracers (89Zr-antibody, 68Ga/18F-nanobody) enter phase 1 to map antigen, guide choice, and monitor loss. ctDNA and SLFN11/TOP1 biomarkers for payload resistance are under study.
- 2027+speculative45%–70%likely
Next generation: bispecific and next-payload TROP2 ADCs
Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103), TROP2 ADCs with non-TOP1 or dual payloads, TROP2-directed radioconjugates, and TROP2 CAR-T. The class moves into early-stage disease (neoadjuvant/post-neoadjuvant TNBC) and into lung, gastric, and endometrial cancer. A TROP2 PET-guided, payload-switching treatment algorithm is the field's implicit goal.
Probability ranges are named estimates that the claim is borne out on roughly a five-year horizon. They are meant to be argued with: propose a revision with your name and reasoning via a pull request to src/data/confidence.ts.
Story
topTarget discovery and antibody development
TROP2 identified on trophoblasts (1981); overexpression across epithelial cancers established in the 2000s. Immunomedics humanises the RS7 antibody and conjugates SN-38 (IMMU-132) with a moderately stable, hydrolysable linker designed to release payload in the tumour microenvironment.
Sacituzumab govitecan proves the target
ASCENT: OS 12.1 vs 6.7 months in pretreated metastatic TNBC; accelerated then full approval. Gilead acquires Immunomedics for $21B. Benefit irrespective of TROP2 IHC, so no companion diagnostic is required.
The trial that proved a TROP2 ADC could nearly double survival in heavily pretreated triple-negative breast cancer.
The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer.
Gilead owns Trodelvy (via the $21B Immunomedics deal) and the Kite CAR-T franchise.
Second entrant: datopotamab deruxtecan
Datopotamab deruxtecan carries the DXd payload at DAR 4 on a different anti-TROP2 antibody. TROPION-Breast01 (HR+, PFS only) and TROPION-Lung01 (mixed) produce narrow approvals (HR+ breast 2025; EGFR-mutant NSCLC 2025). Stomatitis and ocular toxicity define its profile versus sacituzumab's neutropenia and diarrhoea. Sacituzumab expands to HR+ (TROPiCS-02) but loses its urothelial indication.
Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy.
The trial that got Datroway approved in hormone-positive breast cancer, though it did not extend overall survival.
A TROP2 ADC helped in non-squamous lung cancer but not squamous, and the overall survival result fell short.
First line: three positive phase 3 trials
ASCENT-03 (sacituzumab, PD-1-ineligible), ASCENT-04 (sacituzumab + pembrolizumab, PD-L1+), and TROPION-Breast02 (Dato-DXd, PD-1-ineligible, first OS benefit) all read out positive, with FDA approvals in Q2 2026. TROP2 ADCs displace chemotherapy in first-line metastatic TNBC. TROPION-Breast05 (Dato-DXd + durvalumab) is pending.
Moved Trodelvy into first-line use for triple-negative patients who cannot receive immunotherapy.
Showed that pairing an ADC with immunotherapy beats chemotherapy plus immunotherapy in first-line PD-L1-positive TNBC.
The first trial to show an overall survival benefit for a first-line ADC in triple-negative breast cancer.
Tests whether Dato-DXd plus a PD-L1 blocker beats today's immunotherapy-chemotherapy standard.
Third entrant: sacituzumab tirumotecan and the Merck programme
Kelun's sac-TMT, with a belotecan-derived payload and a more stable linker, is approved in China (2024) and licensed to Merck, which is running >10 phase 3 TroFuse trials across TNBC, HR+ breast, NSCLC, endometrial, and cervical cancer, often with pembrolizumab. FDA priority voucher July 2026; US approval expected to follow positive first-line TNBC data.
Sacituzumab tirumotecan is a third TROP2 ADC from China, licensed to Merck for a very large global programme. It is approved in China; in the US it has a priority voucher but not yet approval.
Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.
Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.
Unsolved: selection, sequencing, resistance
IHC does not predict benefit. Cross-resistance among TOP1 payloads limits sequencing (T-DXd → sacituzumab or vice versa). TROP2 PET tracers (89Zr-antibody, 68Ga/18F-nanobody) enter phase 1 to map antigen, guide choice, and monitor loss. ctDNA and SLFN11/TOP1 biomarkers for payload resistance are under study.
An experimental PET scan that shows whether a tumour carries the TROP2 protein, so doctors could pick the right ADC before giving it.
The open question of whether a second ADC works after the first one fails, especially when both carry the same type of payload.
Giving a second ADC with the same kind of payload straight after the first often does not work well.
Proposed: a TROP2 PET scan to choose between three TROP2 ADCs and predict who will respond, since tissue staining has not worked.
Next generation: bispecific and next-payload TROP2 ADCs
Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103), TROP2 ADCs with non-TOP1 or dual payloads, TROP2-directed radioconjugates, and TROP2 CAR-T. The class moves into early-stage disease (neoadjuvant/post-neoadjuvant TNBC) and into lung, gastric, and endometrial cancer. A TROP2 PET-guided, payload-switching treatment algorithm is the field's implicit goal.
AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.
A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue.
A dual-payload ADC is an ADC carrying two different poisons at once, so the tumour cannot escape by becoming resistant to one.
Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.
Use a whole-body TROP2 scan instead of a single tissue stain to decide which patients get a TROP2 ADC, which one, and when to switch.